Literature DB >> 27831649

MiR-129-5p is downregulated in breast cancer cells partly due to promoter H3K27m3 modification and regulates epithelial-mesenchymal transition and multi-drug resistance.

Q-X Luan1, B-G Zhang, X-J Li, M-Y Guo.   

Abstract

OBJECTIVE: In this study, we firstly studied whether H3K27me3 modification is a mechanism of miR-129-5p downregulation in breast cancer and further investigated the functional role of miR-129-5p in epithelial-to-mesenchymal transition (EMT) and in multi-drug resistance (MDR) of the cancer cells.
MATERIALS AND METHODS: Immunoprecipitation (IP) and Chromatin Immunoprecipitation (ChIP) assay were performed to detect the association among SOX4, EZH2 and H3K27me3 and their enrichment in the promoter region of miR-129-2. Western blot and immunofluorescent staining were performed to detect the expression of epithelial and mesenchymal markers. MTT assay was applied to test drug sensitivity.
RESULTS: Enforced EZH2 and SOX4 expression resulted in suppressed miR-129-5p level in MCF-7 cells. There was an interaction among SOX4, EZH2 and H3K27me3 modification and they were significantly enriched in the region upstream of transcription start of miR-129-2. MCF-7 cells transfected with miR-129-5p mimics had significantly suppressed SOX4 expression. MCF-7 cells with miR-129-5p overexpression had significantly restored E-cadherin expression and suppressed N-cadherin and Vimentin expression. The drug sensitivity assay showed that miR-129-5p substantially reduced IC50 of ADM, VCR and PTX in MCF-7/ADM cells
CONCLUSIONS: There is a reciprocal regulation between miR-129-5p and SOX4 via the SOX4/EZH2 complex mediated H3K27me3 modification in breast cancer cells. MiR-129-5p is an important miRNA modulating EMT and MDR in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27831649

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  19 in total

1.  Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation.

Authors:  Jin Gao; Yuan Yuan; Lili Zhang; Shaorong Yu; Jianwei Lu; Jifeng Feng; Sainan Hu
Journal:  Cancer Cell Int       Date:  2020-03-23       Impact factor: 5.722

2.  Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial-mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2.

Authors:  Zhenming Jiang; Yuxi Zhang; Xi Chen; Pingeng Wu; Dong Chen
Journal:  Cancer Cell Int       Date:  2019-10-21       Impact factor: 5.722

Review 3.  Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?

Authors:  Yong Weon Yi; Kyu Sic You; Jeong-Soo Park; Seok-Geun Lee; Yeon-Sun Seong
Journal:  Int J Mol Sci       Date:  2021-12-21       Impact factor: 5.923

Review 4.  Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

Authors:  Muhammad Tufail; Jia Cui; Changxin Wu
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 5.  Review article epithelial to mesenchymal transition‑associated microRNAs in breast cancer.

Authors:  Hossein Javdani; Homa Mollaei; Farzaneh Karimi; Shiva Mahmoudi; Ali Farahi; Mohamad Javad Mirzaei-Parsa; Arman Shahabi
Journal:  Mol Biol Rep       Date:  2022-06-18       Impact factor: 2.742

6.  MicroRNA-129-5p is regulated by choline availability and controls EGF receptor synthesis and neurogenesis in the cerebral cortex.

Authors:  Isis Trujillo-Gonzalez; Yanyan Wang; Walter B Friday; Kasey C Vickers; Cynthia L Toth; Lorian Molina-Torres; Natalia Surzenko; Steven H Zeisel
Journal:  FASEB J       Date:  2018-12-06       Impact factor: 5.834

7.  Expression and clinical significance of SATB1 and TLR4 in breast cancer.

Authors:  Xuebo Wang; Xiumei Yu; Qingli Wang; Yingying Lu; Haixia Chen
Journal:  Oncol Lett       Date:  2017-07-12       Impact factor: 2.967

8.  microRNA expression profiles of scar and normal tissue from patients with posterior urethral stricture caused by pelvic fracture urethral distraction defects.

Authors:  Kaile Zhang; Jun Chen; Dongliang Zhang; Lin Wang; Weixin Zhao; David Yun-Te Lin; Rong Chen; Hong Xie; Xiaoyong Hu; Xiaolan Fang; Qiang Fu
Journal:  Int J Mol Med       Date:  2018-02-12       Impact factor: 4.101

9.  Inactivation of the Wnt/β-catenin signaling pathway underlies inhibitory role of microRNA-129-5p in epithelial-mesenchymal transition and angiogenesis of prostate cancer by targeting ZIC2.

Authors:  Zhenming Jiang; Yuxi Zhang; Xi Chen; Pingeng Wu; Dong Chen
Journal:  Cancer Cell Int       Date:  2019-10-21       Impact factor: 5.722

10.  BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Authors:  Kathleen Gebhardt; Bayram Edemir; Elisabeth Groß; Linda Nemetschke; Stefanie Kewitz-Hempel; Rose K C Moritz; Cord Sunderkötter; Dennis Gerloff
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.